Impact of Dual Interleukin‐ 17A and Interleukin‐ 17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open‐Label Extension

Maksymowych, WP; Ramiro, S; Poddubnyy, D; Baraliakos, X; Lambert, RGW; Massow, U; Vaux, T; Prajapati, C; Marten, A; de Peyrecave, N; Østergaard, M

doi:10.1002/art.70336

Impact of Dual Interleukin‐ 17A and Interleukin‐ 17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open‐Label Extension

Arthritis RheumatolPublished 14 Sep 2026Secondary analysis of the BE MOBILE 1 and 2 phase 3 randomised trials and their open-label extension

Read the original article ↗PubMed

Cite

Authors' conclusion

Dual inhibition of IL-17A and IL-17F with bimekizumab led to substantial reductions in MRI SIJ/spine inflammation, gradual decreases in SIJ erosion, and minimal radiographic progression in the SIJ/spine in patients with axSpA.

Study context

Population: Patients with axSpA (nr-axSpA in BE MOBILE 1; r-axSpA in BE MOBILE 2) in magnetic resonance imaging (MRI) substudies and with baseline and week 104 radiographs

Comparison: Bimekizumab 160 mg SC every 4 weeks vs placebo, then all on bimekizumab

Methodological detailsdouble-blind, placebo-controlled, MRI substudies, observed case data

Double-blind
Placebo-controlled
MRI substudies
Observed case data

Primary result

As reported in the abstract

MRI inflammation, mean change from baseline (bimekizumab-randomized) · week 52

Spondyloarthritis Research Consortium of Canada (SPARCC) sacroiliac joints (SIJ), nr-axSpA

−7.6

SPARCC SIJ, r-axSpA

−5.1

Berlin spine, nr-axSpA

−0.5

Berlin spine, r-axSpA

−2.5

Further findings

SPARCC SIJ structural score components, mean change from baseline · week 52

Erosion, nr-axSpA: −1.8
Erosion, r-axSpA: −1.8
Backfill, nr-axSpA: 0.9
Backfill, r-axSpA: 0.6
Fat lesion, nr-axSpA: 0.7
Fat lesion, r-axSpA: 0.5
Ankylosis, nr-axSpA: 0.0
Ankylosis, r-axSpA: 0.2

Radiographic progression, mean change from baseline · week 104

mNY, nr-axSpA: 0.03
mSASSS, r-axSpA: 0.3

Original publication

Impact of Dual Interleukin‐ 17A and Interleukin‐ 17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open‐Label Extension. Arthritis Rheumatol. Published 14 September 2026. doi:10.1002/art.70336

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →